If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Trading Update & Announcement of Investor Seminar

11 Jan 2024 07:00

RNS Number : 3183Z
GlobalData PLC
11 January 2024
 

11 January 2024

 

GlobalData Plc

(AIM: DATA, "GlobalData", the "Group")

 

Full year trading update and announcement of Investor Seminar

 

GlobalData Plc, a leading data, analytics, and insights platform, today provides the following update on trading following the end of its financial year to 31 December 2023 ("FY2023").

 

Following its interim results on 31 July 2023, GlobalData continued to deliver strong profitable growth throughout the second half. For FY2023, the Group expects to deliver Group revenue of c.£273m (2022: £243m), reflecting annual growth of 12% (7% underlying), and adjusted EBITDA growth of 28% to c.£111m (2022: £86m), which is within range of market expectations for the year. EBITDA margin was strong at c.41% (2022: 36%).

 

On 21 December 2023, we announced the launch of our new growth plan and Group reorganisation to operate across three customer-focused divisions - Healthcare, Consumer, and Technology - and also the transaction to sell a minority stake in our Healthcare business, which accounted for c.36% of revenue, at a valuation of £1,115m, raising net cash proceeds of approximately £434m.The transaction, which will provide flexibility for accelerated value-creating M&A across the Group, is progressing in line with our expectations and we expect to complete in Q2 2024.

 

GlobalData will host an investor and analyst seminar to focus on the new growth strategy and the customer-focused divisions, as well as further information on the impact of the Healthcare transaction on 24 January 2024 at 2pm. Please register your interest to attend this event with globaldata@fticonsulting.com.

 

FY2023 results, in full, will be announced on 4 March 2024.

 

Mike Danson, Chief Executive Officer of GlobalData Plc, commented:

 

"Over the last year, GlobalData has continued to execute on its growth optimisation plan and provide its global customer base with mission-critical insights and analysis. The result of this is we exited 2023 with another period of strong profitable growth and an EBITDA margin of more than 40%.

 

As we look ahead, we enter 2024 with a new growth plan and operating structure, which when added to our strong financial position, allows GlobalData to pursue a more ambitious growth strategy across the three divisions and create substantial value over the medium term."

 

 

ENDS

 

 

ENQUIRIES

 

GlobalData Plc

Mike Danson, Chief Executive Officer

0207 936 6400

Graham Lilley, Chief Financial Officer

J.P. Morgan Cazenove (Nomad, Joint Broker)

0203 493 8000

Bill Hutchings

Mose Adigun

Panmure Gordon (Joint Broker)

0207 886 2500

Rupert Dearden

Dougie McLeod

Deutsche Numis Securities (Joint Broker)

Nick Westlake

Iqra Amin

 

0207 260 1000

FTI Consulting (Financial PR)

0203 727 1000

Edward Bridges

Dwight Burden

Emma Hall

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFAESSELSEDF

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.